title: Tesamorelin.
abstract: In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
authors.forename: Carl
authors.initials: C
authors.lastname: Grunfeld
authors.forename: Argyris
authors.initials: A
authors.lastname: Dritselis
authors.forename: Peter
authors.initials: P
authors.lastname: Kirkpatrick
mesh_terms: D050153:Abdominal Fat / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods; D013007:Growth Hormone-Releasing Hormone / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans
chemical_list: D013007:Growth Hormone-Releasing Hormone; C479538:tesamorelin